Exchange: NASDAQ·Updated 07:30 PM EST

BLRX News

News
all
press releases
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026 BioLineRx to Report Third Quarter 2026 Results on November 23, 2026PR NewswireTEL AVIV, Israel, Nov. 18, 2026 Management to Hold Conference Call at 8:30 a.m. ESTTEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026 BioLineRx to Report Third Quarter 2026 Results on November 23, 2026PR NewswireTEL AVIV, Israel, Nov. 18, 2026 Management to Hold Conference Call at 8:30 a.m. ESTTEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire
More News
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus CapitalPR NewswireTEL AVIV, Israel, Nov. 18, 2026 - Transaction provides non-dilutive capital through sale of BioLineRx's portion...
PR Newswire
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026PR NewswireTEL AVIV, Israel and OSLO, Norway...
PR Newswire
The 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, November 13-15, is bringing together an unusually broad group of biotechnology companies pursuing new approaches to some of the most difficult-to-treat brain cancers. Among the participants are NeOnc Technologies Holdings (NASDAQ: NTHI), Nuvation Bio (NYSE: NUVB), Jazz Pharmaceuticals (NASDAQ: JAZZ), Cerenome (NASDAQ: CNSY), BioLineRx (NASDAQ: BLRX), Alpha Tau Medical (NASDAQ: DRTS), and privately held Diakonos Oncology. Their programs range from targeted drugs and immunotherapy to localized radiation and experimental drug-delivery technologies.The 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, November 13-15, is bringing together an unusually broad group of biotechnology companies pursuing new approaches to some of the most difficult-to-treat brain cancers. Among the participants are NeOnc Technologies Holdings (NASDAQ: NTHI), Nuvation Bio (NYSE: NUVB), Jazz Pharmaceuticals (NASDAQ: JAZZ), Cerenome (NASDAQ: CNSY), BioLineRx (NASDAQ: BLRX), Alpha Tau Medical (NASDAQ: DRTS), and privately held Diakonos Oncology. Their programs range from targeted drugs and immunotherapy to localized radiation and experimental drug-delivery technologies.
24-7 Market News
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026PR...
PR Newswire
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel...
PR Newswire
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a...
PR Newswire
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 31, 2026 - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third...
PR Newswire
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PR Newswire TEL AVIV, Israel, Aug. 28, 2026 TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PR Newswire TEL AVIV, Israel, Aug. 25, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire

Advertisement|Remove ads.